替考拉宁治疗呼吸机相关性肺炎疗效与安全性评价

发布时间：2018-05-03 05:41

本文选题：替考拉宁 + 万古霉素　；参考：《中华医院感染学杂志》2014年11期

【摘要】：目的评价替考拉宁治疗呼吸机相关性肺炎(VAP)的疗效与安全性。方法选择2010年3月-2013年1月入住医院ICU革兰阳性球菌感染导致的VAP患者87例,将其随机分为试验组和对照组,其中试验组44例患者给予国产替考拉宁400mg静脉滴注,12h给药1次,3个剂量后改为24h给药1次;对照组43例患者给予万古霉素1.0g静脉滴注,12h给药1次,比较两组患者临床疗效、细菌学疗效及不良反应发生率。结果临床痊愈率、有效率、细菌学清除率试验组分别为47.73%、79.55%、86.36%;对照组分别为53.49%、81.40%、88.40%,经χ2检验,差异无统计学意义;试验组与对照组的不良反应发生率分别为6.80%和9.30%,两组比较差异无统计学意义。结论国产替考拉宁治疗革兰阳性球菌引起的呼吸机相关性肺炎(VAP)疗效确切、安全性高,临床上确诊及高度怀疑革兰阳性球菌引起的VAP患者,可作为首选药物。
[Abstract]:Objective to evaluate the efficacy and safety of teicoplanin in the treatment of ventilator-associated pneumonia (VAP). Methods from March 2010 to January 2013, 87 patients with VAP caused by ICU Gram positive cocci infection were randomly divided into experimental group and control group. 44 patients in the test group were given domestic teicoplanin 400mg intravenously for 12 h, 3 doses were changed to 24 hours, and 43 patients in the control group were given vancomycin 1.0 g intravenously for 12 hours. The clinical efficacy of the two groups was compared. Bacteriological efficacy and incidence of adverse reactions. Results the clinical cure rate, effective rate and bacteriological clearance rate in the experimental group were 47.733.79.55 and 86.360.In the control group, they were 53.490.81.408.40 and 88.40, respectively. The difference was not statistically significant by 蠂 2 test. The incidence of adverse reactions in the test group and the control group was 6.80% and 9.30% respectively, and there was no significant difference between the two groups. Conclusion domestic teicoplanin is effective and safe in the treatment of patients with VAP caused by Gram-positive cocci.
【作者单位】：辽宁省人民医院ICU;
【基金】：辽宁省科技厅科技基金资助项目(2010225036)
【分类号】：R563.1

【参考文献】